Jesinghaus, M.* ; Boxberg, M.* ; Wilhelm, D.* ; Münch, S.* ; Dapper, H.* ; Quante, M.* ; Schlag, C.* ; Lange, S.* ; Budczies, J.* ; Konukiewitz, B.* ; Mollenhauer, M.* ; Schlitter, A.M.* ; Becker, K.F.* ; Feith, M.* ; Friess, H.* ; Steiger, K.* ; Combs, S.E. ; Weichert, W.*
Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinoma.
Br. J. Cancer 121, 1050-1057 (2019)
BACKGROUND: Cellular Dissociation Grade (CDG) composed of tumour budding and cell nest size has been shown to independently predict prognosis in pre-therapeutic biopsies and primary resections of oesophageal squamous cell carcinoma (ESCC). Here, we aimed to evaluate the prognostic impact of CDG in ESCC after neoadjuvant therapy.METHODS: We evaluated cell nest size and tumour budding activity in 122 post-neoadjuvant ESCC resections, correlated the results with tumour regression groups and patient survival and compared the results with data from primary resected cases as well as pre-therapeutic biopsies.RESULTS: CDG remained stable when results from pre-therapeutic biopsies and post-therapeutic resections from the same patient were compared. CDG was associated with therapy response and a strong predictor of overall, disease-specific (DSS) and disease-free (DFS) survival in univariate analysis and-besides metastasis-remained the only significant survival predictor for DSS and DFS in multivariate analysis. Multivariate DFS hazard ratios reached 3.3 for CDG-G2 and 4.9 for CDG-G3 neoplasms compared with CDG-G1 carcinomas (p = 0.016).CONCLUSIONS: CDG is the only morphology-based grading algorithm published to date, which in concert with regression grading, is able to contribute relevant prognostic information in the post-neoadjuvant setting of ESCC.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Useful Prognostic Marker; Phase-iii Trial; Predicts Prognosis; Surgery; Cancer; Chemoradiotherapy; Chemotherapy; Radiotherapy; Regression; Features
Keywords plus
Language
english
Publication Year
2019
Prepublished in Year
HGF-reported in Year
2019
ISSN (print) / ISBN
0007-0920
e-ISSN
1532-1827
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 121,
Issue: 12,
Pages: 1050-1057
Article Number: ,
Supplement: ,
Series
Publisher
Nature Publishing Group
Publishing Place
Macmillan Building, 4 Crinan St, London N1 9xw, England
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Radiation Sciences
PSP Element(s)
G-501300-001
Grants
Copyright
Erfassungsdatum
2019-11-14